178 related articles for article (PubMed ID: 31752449)
1. Molecular Signatures for Combined Targeted Treatments in Diffuse Malignant Peritoneal Mesothelioma.
Belfiore A; Busico A; Bozzi F; Brich S; Dallera E; Conca E; Capone I; Gloghini A; Volpi CC; Cabras AD; Pilotti S; Baratti D; Guaglio M; Deraco M; Kusamura S; Perrone F
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31752449
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of miR-34a in peritoneal mesothelioma relies on c-MET and AXL inhibition: persistent activation of ERK and AKT signaling as a possible cytoprotective mechanism.
El Bezawy R; De Cesare M; Pennati M; Deraco M; Gandellini P; Zuco V; Zaffaroni N
J Hematol Oncol; 2017 Jan; 10(1):19. PubMed ID: 28100259
[TBL] [Abstract][Full Text] [Related]
3. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
4. miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.
Cimino-Reale G; Gandellini P; Santambrogio F; Recagni M; Zaffaroni N; Folini M
J Hematol Oncol; 2017 Jul; 10(1):140. PubMed ID: 28716051
[TBL] [Abstract][Full Text] [Related]
5. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
[TBL] [Abstract][Full Text] [Related]
6. Receptor tyrosine kinase and downstream signalling analysis in diffuse malignant peritoneal mesothelioma.
Perrone F; Jocollè G; Pennati M; Deraco M; Baratti D; Brich S; Orsenigo M; Tarantino E; De Marco C; Bertan C; Cabras A; Bertulli R; Pierotti MA; Zaffaroni N; Pilotti S
Eur J Cancer; 2010 Oct; 46(15):2837-48. PubMed ID: 20692828
[TBL] [Abstract][Full Text] [Related]
7. Anti-tumor activity of selective inhibitors of XPO1/CRM1-mediated nuclear export in diffuse malignant peritoneal mesothelioma: the role of survivin.
De Cesare M; Cominetti D; Doldi V; Lopergolo A; Deraco M; Gandellini P; Friedlander S; Landesman Y; Kauffman MG; Shacham S; Pennati M; Zaffaroni N
Oncotarget; 2015 May; 6(15):13119-32. PubMed ID: 25948791
[TBL] [Abstract][Full Text] [Related]
8. Diffuse malignant peritoneal mesothelioma: A review.
Sun L; Li C; Gao S
Front Surg; 2022; 9():1015884. PubMed ID: 36684194
[TBL] [Abstract][Full Text] [Related]
9. miR-550a-3p is a prognostic biomarker and exerts tumor-suppressive functions by targeting HSP90AA1 in diffuse malignant peritoneal mesothelioma.
El Bezawy R; Percio S; Ciniselli CM; De Cesare M; Colella G; Dugo M; Veneroni S; Doldi V; Martini S; Baratti D; Kusamura S; Verderio P; Deraco M; Gandellini P; Zaffaroni N; Zuco V
Cancer Gene Ther; 2022 Oct; 29(10):1394-1404. PubMed ID: 35352023
[TBL] [Abstract][Full Text] [Related]
10. Treatment of diffuse malignant peritoneal mesothelioma (DMPM) by cytoreductive surgery and HIPEC.
Robella M; Vaira M; Mellano A; Marsanic P; Cinquegrana A; Borsano A; Barbera M; Caneparo A; Siatis D; Sottile A; De Simone M
Minerva Chir; 2014 Feb; 69(1):9-15. PubMed ID: 24675242
[TBL] [Abstract][Full Text] [Related]
11. CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts.
De Cesare M; Sfondrini L; Pennati M; De Marco C; Motta V; Tagliabue E; Deraco M; Balsari A; Zaffaroni N
J Transl Med; 2016 Jan; 14():25. PubMed ID: 26810896
[TBL] [Abstract][Full Text] [Related]
12. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
Davidson B; Zhang Z; Kleinberg L; Li M; Flørenes VA; Wang TL; Shih IeM
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5944-50. PubMed ID: 17062665
[TBL] [Abstract][Full Text] [Related]
13. p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
Ito T; Hamasaki M; Matsumoto S; Hiroshima K; Tsujimura T; Kawai T; Shimao Y; Marutsuka K; Moriguchi S; Maruyama R; Miyamoto S; Nabeshima K
Am J Clin Pathol; 2015 Jun; 143(6):830-8. PubMed ID: 25972325
[TBL] [Abstract][Full Text] [Related]
14. Combined MEK and PI3K/p110β Inhibition as a Novel Targeted Therapy for Malignant Mesothelioma Displaying Sarcomatoid Features.
Marqués M; Tranchant R; Risa-Ebrí B; Suárez-Solís ML; Fernández LC; Carrillo-de-Santa-Pau E; Del Pozo N; Martínez de Villarreal J; Meiller C; Allory Y; Blum Y; Pirker C; Hegedus B; Barry ST; Carnero A; Berger W; Jean D; Real FX
Cancer Res; 2020 Feb; 80(4):843-856. PubMed ID: 31911549
[TBL] [Abstract][Full Text] [Related]
15. Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.
Lund-Andersen C; Nakken S; Nygård S; Fromm B; Aasheim LB; Davidson B; Julsrud L; Abrahamsen TW; Kristensen AT; Dybdahl B; Larsen SG; Hovig E; Flatmark K
Cold Spring Harb Mol Case Stud; 2019 Apr; 5(2):. PubMed ID: 30862609
[TBL] [Abstract][Full Text] [Related]
16. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study.
Hommell-Fontaine J; Isaac S; Passot G; Decullier E; Traverse-Glehen A; Cotte E; You B; Mohamed F; Gilly FN; Glehen O; Berger F
Ann Surg Oncol; 2013 Nov; 20(12):3892-8. PubMed ID: 23800898
[TBL] [Abstract][Full Text] [Related]
17. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
[TBL] [Abstract][Full Text] [Related]
18. [Diffuse malignant peritoneal mesothelioma (DMPM) - a rare diagnosis].
Habbel VSA; Mahler EA; Feyerabend B; Oldhafer KJ; Lipp MJ
Z Gastroenterol; 2020 Feb; 58(2):146-151. PubMed ID: 32050285
[TBL] [Abstract][Full Text] [Related]
19. Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).
Baratti D; Kusamura S; Cabras AD; Bertulli R; Hutanu I; Deraco M
Eur J Cancer; 2013 Oct; 49(15):3140-8. PubMed ID: 23831335
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of CD74, CD10 and Ki-67 immunohistochemical expression in patients with diffuse malignant peritoneal mesothelioma: a retrospective study.
Liang Y; Li C; Liu Y; Tian L; Yang D
BMC Cancer; 2023 May; 23(1):406. PubMed ID: 37147569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
